INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2013

Short-term soy isoflavone supplementation did not alter serum hormones or PSA in prostate cancer.

Eighty-six men awaiting prostatectomy were randomized to consume 80 mg daily of isoflavones or a placebo for up to six weeks. Microarray analysis revealed down-regulation of 12 cell cycle control genes and 9 apoptosis genes in tumor tissue from the supplement arm. However, shifts in circulating estrogens, androgens, PSA, and total cholesterol showed no statistically significant differences between groups.

Study type
Randomized controlled trial
Who was studied
86 men with localized prostate cancer
What was measured
Serum hormones, PSA, cholesterol, and tissue gene expression

THE PAPER

Short-term soy isoflavone intervention in patients with localized prostate cancer: a randomized, double-blind, placebo-controlled trial.

Hamilton-Reeves JM, Banerjee S, Banerjee SK, Holzbeierlein JM, Thrasher JB, Kambhampati S, Keighley J, Van Veldhuizen P. PLoS One, 2013.

PubMed 23874588 ↗DOI 10.1371/journal.pone.0068331 ↗

Cancer

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.